Off-Label Medical Device Promotion: What the Sales Team Taught and the Hospital Billed

Medical device off-label promotion means marketing a device for a use outside the labeling cleared or approved by the Food and Drug Administration. A sales team may teach physicians one use while the instructions for use describe another. Reimbursement staff may then supply the billing advice that helps sell the procedure. For an insider, the story is in those connections: what the company wanted physicians to do, what patients received, and what the government paid for.

Is Off-Label Use Illegal?

No. A physician may lawfully use a legally marketed device off-label within a legitimate physician-patient relationship. A manufacturer’s promotion can break the law when it markets a device for a changed use without the required authorization. Our whistleblower experts examine what the business designed, distributed and promoted, and how that reached the provider’s bill.

A sales representative, clinical specialist or regulatory employee may hear that the physician chose the use. The physician’s decision is one part of the transaction. The manufacturer’s training, product design, instructions and reimbursement advice show how the company influenced that decision.

What Is the FDA Definition of Off-Label Use?

For a medical device, off-label use means use outside its cleared or approved labeling. The indication and the configuration matter: the particular purpose, the product used and the instructions that accompanied it.

False authorization claims add another problem. In the NuVasive whistleblower complaint, a former sales representative alleged that training and promotional materials represented CoRoent XL implants as indicated for use at more than two spinal levels. The complaint alleged that the indication did not cover that use. The difference was between the authorization the company had and the authorization its customers were told it had.

How Intended Use Moves Beyond the Label

Intended use can emerge from product design, composition, statements and the circumstances of distribution. The Food and Drug Administration’s rule effective September 1, 2021 expressly includes design and composition as evidence of intended use.

Internal marketing plans and instructions to the field can show what use the business was actually pursuing. An instruction to prepare the product differently may tell more than the approved brochure.

When the Preparation Changes the Product

In its deferred prosecution agreement, Genzyme admitted that representatives helped prepare Seprafilm slurry, an example of unauthorized medical device modification.

When Off-Label Promotion Becomes a False Claim

A manufacturer can face a False Claims Act case when it knowingly causes a provider to submit a false government claim. The manufacturer may supply the sales pitch and billing advice while the hospital or physician submits the bill.

The device business makes that separation especially important. A physician may choose or strongly influence the product. The hospital buys it. With consigned inventory, the manufacturer may retain ownership until use or implantation. The representative who supports the procedure may also manage the inventory and instrument trays. Product selection, use and the sale can meet in the operating room.

Medicare usually packages an implanted device’s cost into payment for the procedure or hospital stay. The claim worth examining may therefore describe the service rather than carry a separate price for the implant. We connect the product and procedure records to the payment the provider requested.

The Food and Drug Administration authorizes marketing, while Medicare determines coverage and payment. The code on a claim describes the item or service the provider says it delivered.

The Medicare coverage law requires covered care to be reasonable and necessary. Billing advice that describes one procedure while the provider performs another supplies a particularly direct connection.

A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, published in the Journal of Forensic and Investigative Accounting in 2020, distinguishes inaccurate descriptions of goods or services from false claims of compliance with payment conditions. That distinction gives the investigation two useful questions: what did the bill say the patient received, and what did the payer require before paying for it?

Medical Device Off-Label Promotion Cases

The cases connect the sales instruction to a specific treatment: a saline spacer used for steroid delivery, a vein-treatment kit promoted beyond its clearance, and beads marketed to deliver drugs.

Acclarent’s Saline Spacer Was Sold for Steroid Delivery

Acclarent’s Relieva Stratus was cleared as a sinus spacer used with saline. The court opinion in the criminal case against its former executives describes the company asking the Food and Drug Administration to add a therapeutic-agent use. In May 2007, the agency rejected that request and told Acclarent the changed intended use required a new clearance submission.

The court’s account of the criminal trial describes evidence of marketing strategy, product design and regulatory strategy alongside promotional statements. The jury found the former chief executive and sales vice president guilty of distributing a device that lacked the clearance its intended use required.

In July 2016, Acclarent separately agreed to an $18 million civil settlement. The government alleged that marketing and distributing the spacer for drug delivery caused providers to submit false claims to Medicare and other federal healthcare programs. That allegation connected the manufacturer’s sales conduct to providers’ bills.

Vascular Solutions’ Civil Settlement and Criminal Acquittal

Vascular Solutions agreed to a $520,000 civil settlement in July 2014 over allegations concerning Vari-Lase promotion for perforator-vein ablation. The allegations concerned promotion despite a failed trial and lack of authorization for that use from the Food and Drug Administration.

A jury acquitted the company and its chief executive in the separate criminal case in February 2016.

AngioDynamics provides a useful comparison at the reimbursement end. According to the government’s account of its perforator-kit allegations, the Food and Drug Administration declined to add perforator-vein treatment to the kit’s clearance. The company recalled and renamed the product, but certain personnel allegedly continued promoting that use and falsely told providers Medicare would cover it despite coverage restrictions. The coverage representation is the part a reimbursement employee would recognize.

Biocompatibles’ Beads and the Codes Used to Bill

The government alleged that Biocompatibles promoted LC Bead as a drug-delivery product. In the November 2016 resolution, the company pleaded guilty to misbranding and separately agreed to a $25 million civil settlement.

The government’s civil account described LC Bead combined with prescription drugs as a new drug-device product that lacked the Food and Drug Administration’s approval or clearance and was not covered by Medicare and other federal health care programs. The whistleblower’s complaint then identified the billing mechanism:

The complaint also alleged that providers were encouraged to use intravenous-injection codes to conceal delivery of the drug through the beads. The alleged scheme reached both descriptions: what procedure took place and how the drug entered the patient. An ordinary-looking code could carry a materially different treatment.

What Evidence Is Needed to Prove Fraud?

The useful evidence connects the authorized device, the company’s instructions, the treatment and the bill. Clearance correspondence and instructions for use describe the starting product. Design records and preparation instructions show what changed. Training materials, sales directions and reimbursement communications show how the company brought that use to customers.

A complaint against NuVasive makes the comparison visible. The whistleblower alleged:

The picture sold the configuration that the footnote disclaimed. That is the contradiction the complaint alleged, and it gives a product specialist something specific to recognize.

Different employees see different parts of the same case. Regulatory staff may know what the Food and Drug Administration refused. Sales and clinical staff may know what customers were taught. Reimbursement staff may know which codes the company supplied. The procedure record and claim connect those instructions to what the provider did and requested payment for.

We work across those records with you. The question is how a commercial decision reached a particular government claim, including what the people directing it understood.

Scientific Information and the Sales Plan

Scientific communications deserve the same attention as sales materials when they are part of the alleged promotion. The NuVasive complaint alleged that employees ghostwrote and edited articles submitted under the names of physicians who used the implants heavily and received payment to lend their names. It also alleged that paid proctor surgeons presented off-label techniques at company-funded meals.

The Biocompatibles complaint alleged that medical science liaisons, presented as a way to prevent off-label promotion, helped sell the product for that use. These allegations put the commercial purpose of the communication in view: who prepared it, who paid for it and how it supported product use.

For an insider in medical affairs or physician education, drafts, speaker arrangements and sales instructions can explain how a scientific message was built.

Can a Whistleblower Take Legal Action Against a Medical Device Company?

A whistleblower can bring a qui tam case under the False Claims Act when a medical device company knowingly causes false government claims. Acclarent’s civil allegations illustrate the connection between the manufacturer and providers’ bills. The Biocompatibles complaint alleged that coding instructions encouraged providers to conceal drug delivery through beads and submit false claims.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

Your role may put you at the point where the sales instruction, clinical use or billing advice changed. Our work is to connect what you know about that decision to the claims it produced and build the case with you.

When You Know What Customers Were Taught

If you saw the company promote a different use, teach a preparation method or supply billing advice that concealed the treatment, speak to one of our whistleblower experts about the instructions behind those claims. We build the connection between the sales decision and the government payment with you, bring in medical device fraud whistleblower lawyers who understand promotion and reimbursement, and stay beside you through the case.